Abstract Application of tetrameric MHC class I-peptide complexes has signiWcantly improved the monitoring of antigen-speciWc T cell immune responses in mouse models as well as in clinical studies. Especially MHC class I tetramer analysis of tumor-speciWc T cells in suspension or on thick vibratome sections from viable tissue has been proven extremely useful. Using the well-characterized mouse tyrosinase-related-protein-2 speciWc cytotoxic T cell (CTL) clone LP9, we now developed a method that allows for speciWc identiWcation of T cells with MHC class I tetramers in 8 m thick, chemically Wxed cryosections. The protocol was validated in a murine inXuenza virus-infection model. Moreover, analysis of delayed type hypersensitivity (DTH) skin biopsies from melanoma patients vaccinated with peptide-loaded mature dendritic cells, revealed the presence and location of anti-tumor CTLs. The speciWcity of the CTLs detected in situ correlated with both the DTH challenge speciWcity and reactivity of cell suspensions derived from the same biopsies. Collectively, our data demonstrate that in situ MHC class I tetramer staining provides a valuable tool to reveal the presence and anatomical location of speciWc CTLs in frozen tissue following immunebased treatment strategies in cancer patients.
Introduction
Immune-based treatment strategies are considered a valuable treatment option for cancer patients. Objective responses have been obtained with a variety of immunotherapy approaches especially in melanoma patients [18, 20] . Recently dendritic cell (DC)-based vaccination studies have received increasing attention and yielded promising results in cancer patients [5, 13, 16, 17, 19, 32] . Development and validation of immunologically based treatment strategies is, however, critically dependent on appropriate monitoring of both the immunological response and the clinical response to deWne the correlates of treatment eYcacy [6, 25] . The availability of soluble multimeric MHC-peptide complexes has broadened the options for immune monitoring since speciWc CTLs can be identiWed and isolated directly [1, 22, 34] . In most studies MHC class I tetramers were only eVective for analysis of T cells that are in suspension [24, 26] . However, like for functional T cell assays, e.g., ELI-spot assay and cytotoxicity assay, this does not yield any information regarding the localization of speciWc T cells within tissues [7, 8, 15, 23] . Therefore, in situ detection of speciWc T cells in tissues would be highly informative in revealing the location and unraveling possible mechanisms of the anti-tumor response in vivo. In this paper we report on the development of a protocol that allows for in situ detection of antigen speciWc T-cells in frozen and Wxed tissue sections. The protocol was Wrst developed using mouse H-2K b -TRP2 180 tetramers and a mouse tissue model containing TRP2-speciWc CTLs [28] . Validation of the protocol was performed in a murine viral infection model and in delayed type hypersensitivity (DTH) biopsies from melanoma patients treated with tumor peptide-loaded DCs [9] .
Materials and methods

MHC class I tetramers
Tetrameric, MHC class I-peptide complexes with speciWcities for mouse H-2K b -TRP2 180-187 , H-2K b -OVA 257-264 , H-2D b -inXuenza A virus NP [366] [367] [368] [369] [370] [371] [372] [373] [374] , and human HLA-A2.1-gp100 [154] [155] [156] [157] [158] [159] [160] [161] [162] ; HLA-A2.1-gp100 280-288 and HLA-A2.1-tyrosinase [369] [370] [371] [372] [373] [374] [375] [376] [377] were kindly provided by Drs T. Schumacher and H. Spits from the Netherlands Cancer Institute (Amsterdam, The Netherlands) or purchased from Immunomics, Beckman Coulter (Inc, San Diego, USA). Other MHC class I tetramers; HLA-A2.1-MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , HLA-A2.1-HIVgag 77-85 and HLA-A2.1-EBV 280-288 were purchased from Immunomics. Each MHC class I tetramer was validated by staining of a CTL line speciWc for HLA-A2.1 in association with the peptide of interest.
Antibodies
Primary antibodies used for the detection of CD8 + cells were WT82 [21] and HIT8a (BD Pharmingen). Secondary antibodies used: biotinylated rabbit anti-streptavidin (code 200-4695), rabbit anti-phycoerythrin (code 200-4199), rabbit anti-streptavidin (code 200-4195) purchased from Rockland Gilbertville, Pa, mouse anti-streptavidin (clone DD9; Upstate Biotechnology) and goat anti-streptavidin (Biogenesis, Poole, UK), goat-anti-rabbit-Alexa594, goatanti-mouse-Alexa498 (Molecular Probes, Europe BV, Leiden, The Netherlands).
Tissues
For development and optimization of a protocol suitable for in situ detection of CTLs we used the H-2K b -restricted TRP2-speciWc clone LP9 [28] . LP9 cells were injected in the hind leg muscles of C57Bl6 mice. After 5 min the mice were sacriWced and the injected muscles were dissected, snap frozen in liquid nitrogen and stored at ¡80°C until further use.
For validation of the optimized protocol developed with the LP9-containing muscle tissue, staining with MHC class I tetramers was also performed on spleens from virusinfected and non-infected B6.Ly5.1 mice and on biopsies from DTH lesions from melanoma patients.
The spleens from B6.Ly5.1 mice were kindly provided by Drs F. Vyth-Dreese and T. Schumacher from the Netherlands Cancer Institute (Amsterdam, The Netherlands). In this virus infection model B6.Ly5.1 mice had received an adoptive transfer of B10F5 lymph node cells. B10F5 mice are transgenic for the H-2D b -restricted, inXuenza A virus NP 366 -speciWc, TCR [14] . Three days after adoptive transfer, part of the mice were infected with inXuenza A virus. Ten days after adoptive transfer spleens were isolated from infected and non-infected mice.
In situ staining with MHC class I tetramer From snap frozen material (muscles or biopsies) 8 m thick cryosections were cut and air-dried and used immediately or stored at ¡80°C until use. Tissue sections were Wxed with 4% paraformaldehyde (PFA) for 3 min. Non-speciWc protein binding was prevented by using 20% normal goat serum in PBS for 20 min. Incubation with MHC class I tetramer was performed overnight at 4°C at an approximate MHC class I tetramer concentration of 5 M in 4% normal goat serum and PBS. After washing with PBS speciWc MHC class I tetramer binding was Wxed with 4% PFA for 20 min. Sections were incubated with or without anti-CD8 at a concentration of 2 g/ml and after washing they were incubated with polyclonal rabbit serum against streptavidine (1/800 diluted, Rockland). Binding of MHC class I tetramer was visualized using a polyclonal goat-anti-rabbitAlexa594 at a 1/500 dilution, resulting in a red Xuorescent signal. CD8 was visualized using a polyclonal goat-antimouse-Alexa498 (1/500 dilution; 30 min at room temperature), resulting in a green Xuorescent signal.
Sections were counterstained with DAPI resulting in a blue Xuorescent staining of the nucleus. Washing in PBS was performed between each incubation. Finally, sections were then mounted with Xuorescent mounting medium containing anti-fade.
FITC and TRITC signals were collected on a Leica Leitz DMRBE. Images were taken using a £10, £40 or £63 objective. Color photomicrographs were generated from electronic overlays.
Patients
Melanoma patients (stage III and IV according to AJCC criteria [4] ) participating in ongoing protocols, in which the immune responses of DC vaccines are studied were included [10] . Eligibility criteria included HLA-A2.1 phenotype, melanoma expressing gp100 and tyrosinase, and WHO performance status 0 or 1. Additional eligibility criteria are described previously. The studies were approved by the local regulatory committee, and written informed consent was obtained from all patients.
Delayed type hypersensitivity
One to 2 weeks after DC vaccination, a DTH skin test was performed. BrieXy, unpulsed DC, DC pulsed with the indicated peptides, DC pulsed with KLH, and DC pulsed with the indicated peptides plus KLH (2-10 £ 10 5 DC each) were injected i.d. [9] . From positive DTH sites (>2 mm), punch biopsies (6 mm) were obtained and cut in half; one part was embedded in Tissue-tek, snap frozen in liquid nitrogen and stored at ¡80°C until further use. The other part was cut in pieces and cultured in RPMI/7%HS supplemented with IL-2 (100 U/ml). Every 7 days, half of the medium was replaced by fresh IL-2-containing RPMI/7%HS. After 2-4 weeks of culturing, T cells were tested for speciWcity.
MHC class I tetramer staining of cells in suspension DTH-derived cells (1 £ 10 5 cells in 10 l) or PBMC (1 £ 10 6 cells in 10 l) were incubated with PE-labeled MHC class I tetramers and FITC-conjugated mAbs either directed against CD4 or CD8 (both Becton Dickinson) for 1 h at RT. After washing, the samples were analyzed by Xow cytometry.
Cytotoxicity assay
Cytotoxic activity of DTH-inWltrated lymphocytes was measured using the chromium release assay as described previously [3] . BrieXy, T2 or BLM cells (a melanoma cell line expressing HLA-A2.1 and no endogenous expression of gp100 and tyrosinase), transfected with control antigen G250, or with the antigens of interest (gp100 and tyrosinase) were incubated with 100 Ci Na 2 
Results and discussion
In situ detection of antigen speciWc T cells with MHC class I tetramers: protocol requirements
To develop a protocol that allows in situ detection of CTLs with MHC class I tetramers on cryo-sections, we used the well-characterized H-2Kb-restricted TRP2 180 -speciWc CTL clone LP9 and the corresponding H-2K b -TRP2 tetramers [28] . As shown in Fig. 1 A-B, LP9 CTLs in suspension were readily stained by TRP2-speciWc tetramers but not by OVA-speciWc tetramers recognizing the OVA SIINFEKL peptide presented by the same H-2K b molecule. For immunocytochemical stainings, cytospins were generated of LP9 cells, either alone or mixed with C57Bl6 thymocytes. ArtiWcial tissues containing LP9 CTLs were obtained by injection of these CTLs in femoral muscles of C57Bl6 mice, and freezing of the dissected injection site. To detect CTLs, cytospins (Fig. 1c-e ) and artiWcial The results demonstrated that the thickness of the tissue sections is of importance for the signal intensity and morphology of the tissue. For tetramer detection of LP9 cells, tissue cryosections of 8 m thick were found to yield a good speciWc signal with adequate morphology (Fig. 1g-l) . Thinner (5 m) or thicker (10 m) sections resulted in a weak speciWc signal and good morphology (5 m) or a good speciWc signal and poorer morphology (10 m) (not shown). An incubation time of 45 min at room temperature with MHC class I tetramers appeared to be superior to overnight incubation at 4°C for tissue sections when no chemical Wxation of the tissue was performed. However, when a mild chemical Wxation (see below) was applied prior to MHC class I tetramer incubation both conditions were similarly eVective.
The use of normal goat serum as a blocking step prior to MHC class I tetramer incubation resulted in an improved signal to noise ratio; however, it also resulted in poorer morphology when used on non-chemically Wxed tissue sections. Fixation of the tissue with 4% PFA before (3 min) and after (20 min) incubation with MHC class I tetramers resulted in stronger speciWc signals and improved morphology (Fig. 1g-l) . Fixation before MHC class I tetramer incubation proved to be a crucial step; Wxation for considerable longer times or higher concentrations of PFA or Wxation with acetone or glutaraldehyde resulted in a strong reduction or even loss of the (speciWc) signal. The Wxation step after MHC class I tetramer incubation merely stabilized the interactions between the T cell receptors and MHC class I tetramers. In summary, optimal speciWc MHC class I tetramer staining with satisfactory morphology was achieved when 8 m thick cryosections were shortly Wxed and preincubated with normal goat serum prior to MHC class I tetramer incubation and followed by Wxation.
A polyclonal rabbit serum recognizing the MHC class I tetramer-associated streptavidin molecules provided signal enhancement that resulted in improved visualization of the speciWc CTL. On both cytospins and LP9-containing muscle tissue sections excellent results were obtained with the ABCkit as a signal ampliWcation and visualization method (Fig. 1c-e, i, l) . Unfortunately, initial tests on murine spleens and human tissue sections, revealed that this ampliWcation and visualization method resulted in high background signals. The background observed upon ampliWcation and visualization with the ABC-kit in these tissues was most likely due to biotin-based, non-speciWc interactions. Therefore, an alternative biotin-independent, Xuorochrome-based ampliWcation and detection method was also developed that yielded excellent signal to noise ratios for those tissues in which the biotin-based protocol was sub-optimal ( Fig. 1m-o) . The established protocols as speciWed in the "Materials and methods" were used for further experiments.
In situ detection of inXuenza virus-speciWc T cells in mice
To validate the developed protocol in a more physiological setting, we applied the virus-infection model previously used to demonstrate in situ tetramer staining on 200-500 m thick viable tissue sections [14] . In this model, lymph node cells of TCR transgenic mice speciWc for the H-2D b -restricted inXuenza A virus NP 366 epitope were transferred to B6.Ly5.1 mice. Mice were then challenged with either inXuenza A virus or with vehicle. Using our protocol, 8 m cryosections from spleens of virus-infected or vehicleinjected B6.Ly5.1 mice were stained with inXuenza A virus-speciWc MHC class I tetramers and CD8. As shown in Fig. 2 , spleens from virus-infected mice contained large clusters of MHC class I tetramer-positive cells (Fig. 2b) whereas only an occasional tetramer positive T cell was detected in spleens from non-infected mice (Fig. 2a) . No MHC class I tetramer positive CD8+ T cells were detected in spleens from virus-infected mice incubated with negative control solution (Fig. 2c, d ). These results indicate that the developed MHC class I tetramer staining protocol speciWcally detected the viral speciWc T cells in 8 m tissue sections equally eVective when compared with the 200-500 m thick viable tissue sections [14] . To determine the applicability of the in situ MHC class I tetramer staining protocol for monitoring the presence of vaccine-related CTLs in melanoma patients, we studied DTH biopsies obtained from melanoma patients participating in ongoing trials at the Radboud University Nijmegen Medical Centre. In these trials melanoma patients are treated with autologous in vitro-generated mature DC loaded with two HLA-A2.1-restricted gp100 epitopes (154-162 and 280-288), an HLA-A2.1-restricted tyrosinase-derived epitope (369-377) and KLH [9, 10] . To investigate the immune response generated in the vaccinated patients, DTH challenges were performed with mature DC and biopsies (6 mm) were taken from positive DTH sites. Eight m thick cryosections were cut from one half of these DTH biopsies and stained according to the developed protocol with a panel of relevant and non-relevant MHC class I tetramers (Table 1) and/or CD8. Initially 3 DTH biopsies from 2 patients (patient 1 and 2) were studied.
Both patients had received DTH with gp100 280 -loaded DCs and one patient also received a DTH with DCs loaded with both gp100 peptides and the tyrosinase peptide (DC + 3 peptides). In patients speciWc staining of clusters of cells with the HLA-A2.1-gp100 280 tetramer was observed whereas no staining with the negative control or any other MHC class I tetramer was detected (Table 1 ; Fig. 3a-f) . In an additional 8 biopsies from 3 patients, MHC class I tetramer positive cells were found in correspondence with the DTH challenge speciWcity, e.g., peptide-speciWc T cells in DTH sites arising from a challenge with DC loaded with peptides and not in DTH sites from unloaded or KLH loaded DC ( Fig. 3g-i ; Table 1 ).
SpeciWc T cells after short term culturing of DTH biopsies
Following a brief culture period, the speciWcity of T cells derived from half of the biopsy was analyzed by conventional methods, e.g., antigen recognition in a cytotoxicity assay or MHC class I tetramer binding. Only a minority of the DTH-derived cells were CD8 positive eVector T cells. The rates of CD4+ and CD8+ T cells derived from DTH cultures varied between biopsies and patients (65 § 21% CD4+ and 27 § 20% CD8+). In 9 out of the 11 biopsies studied, identical T cell speciWcity was observed with the in situ MHC class I tetramer staining and the assays performed on the biopsy outgrowth (Fig. 3c, f, i, j) . In the other two cases (patient 2: DC + 3 peptides, patient 5: DC + 3 peptides) peptide-speciWc T cells were only identiWed with one of the assays. As exempliWed in Fig. 4 , not all cell clusters within a biopsy or tissue section harbor T cells with the same speciWcity. Since the in situ analysis and in vitro assays were performed on diVerent halves of the biopsies some sampling bias may occur. Also some selection of speciWc clones may arise from the brief culture period of the T cells.
CD8 staining
We noted that not all MHC class I tetramer-positive cells were clearly CD8-positive. Variation of the exposure time for the FITC Wlter (visualizing CD8+ cells) revealed a huge range in staining intensities for CD8+ cells (Fig. 5) as also noticed by Denkberg et al. [11] . An increased exposure time for the green Wlter further increased the number of CD8-positive, MHC class I tetramer-positive cells. Competitive binding between CD8 and MHC class I tetramer was also indicated by MHC class I tetramer binding tests of cells in suspension. As shown in Fig. 5 , MHC class I tetramer staining intensity was reduced when the same population of cells was co-stained with CD8 as compared to co-staining with CD4. While for staining of cells in suspension with MHC class I tetramer, samples were incubated at the same time with MHC class I tetramer and CD8, for the in situ protocol, samples were Wrst stained with MHC class I tetramer followed by staining with CD8. This explains possible reduced staining intensity for CD8 in the in situ protocol, and reduced MHC class I tetramer staining intensity for the in vitro staining protocol. In addition, a direct comparison between CD8 staining eYciency in our MHC class I tetramer staining protocol and the more conventional CD8 staining method after acetone Wxation revealed a major diVerence. As shown in Fig. 5 on tissue sections from tonsils, fewer and less intensely stained CD8+ cells are seen with the MHC class I tetramer staining protocol.
Although we can not exclude that a small part of the MHC class I tetramer-positive, CD8-negative cells result from non-speciWc binding of MHC class I tetramer to other non-CD8+ inXammatory cells, our Wndings indicate that: (a) MHC class I tetramer binding only occurred in accordance with the DTH challenge speciWcity, (b) MHC class I tetramer-positive cells were not found using the non-relevant MART-1, HIV and EBV tetramers, only with the tyrosinase and gp100 tetramers, (c) no tyrosinase or gp100-positive cells were found in DTH lesions derived from non-speciWc challenges (i.e., DC alone [n = 4] or DC loaded with KLH [n = 3]), (d) diVerent staining patterns were obtained with the speciWc MHC class I tetramers and (e) the in situ results correlated with the in vitro results on T cell speciWcity clearly argue against a major involvement of non-speciWc binding. It is, however, important to include appropriate controls for the in situ detection of CTLs.
In earlier studies, in situ detection of antigen-speciWc T cells with MHC class I tetramers was performed on viable tissue sections of spleens of T cell receptor transgenic mice or spleens of mice adoptively transferred with speciWc T cells [14, 29, 30] . The application of this method was extended to human T cells in a skin explant assay for graft-versus-host CTL activity [12, 33] . A drawback of the method described in those studies is that it does not allow storage whereas storage of clinical material facilitates retrospective analyses. With the use of multimeric peptide/MHC class I complexes the need for viable material is circumvented, however, these tetramers are not readily available [2, 27, 31] . Therefore the method as we describe, although intricate, is very useful for the analyses of already frozen material from patients treated with peptide-based vaccines. Therefore we believe that this tetramer-based detection of antigen-speciWc T cells in frozen tissue sections may provide a valuable monitoring tool.
